Global Argatroban Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2020-2026

Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5- [(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.
In the last several years, global market of Argatroban Industry decreased with the average production growth rate about -15%. In 2015, global capacity of Argatroban reduced to 34786 grams
from 65183 grams since 2011. It is predicted that the argatroban demand will continue to decrease with a average growth rate of -9% in the coming five years.

Japan is the still largest supplier of argatroban with the production market share of 35% and the consumption market share of 22% in 2015.

The price of argatroban is relatively expensive. The largest consumers are developed countries with high income. USA occupied a market share of 34%. The second place is Europe, following North America with the consumption market share of 22% in 2015.

China has few companies entering the market with production share of only 8%, and demand cannot be satisfied with supply. Large quantities of argatroban have to be imported.

Intially, compared with hirudin and heparin, the therapeutic dose has little effect on platelet, no antigen and strong antithrombotic effect. The sale value has reached 190 million USA dollars in 2008. But because of its narrow therapeutic area, uncertain factors on human’s bodies and fierce competition from other substitutes, it sales far less than other thrombin inhibitor. The value reduced to 101 million USA dollars in 2015.

Market Analysis and Insights: Global Argatroban Market
In 2019, the global Argatroban market size was US$ 60 million and it is expected to reach US$ 19 million by the end of 2026, with a CAGR of -15.0% during 2021-2026.
Global Argatroban Scope and Market Size
Argatroban market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Argatroban market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2015-2026.

Segment by Type, the Argatroban market is segmented into
Argatroban Powder
Argatroban Injection

Segment by Application, the Argatroban market is segmented into
Heparin-induced thrombocytopenia (HIT)
Percutaneous Coronary Intervention
Cerebral arterial thrombosis

Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Competitive Landscape

and Argatroban Market Share Analysis
Argatroban market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2015-2020. Details included are company description, major business, Argatroban product introduction, recent developments, Argatroban sales by region, type, application and by sales channel.

The major companies include:
Pfizer, Inc
SANDOZ
GlaxoSmithKline Plc
fresenius-kabi
Eagle Pharmaceuticals, Inc
Mitsubishi Tanabe Pharma
Teva Pharmaceutical Industries Ltd
WEST-WARD,INC

Frequently Asked Questions